Zacks Research Issues Negative Estimate for CRL Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities research analysts at Zacks Research reduced their Q3 2025 earnings per share (EPS) estimates for shares of Charles River Laboratories International in a report issued on Wednesday, May 28th. Zacks Research analyst R. Department now forecasts that the medical research company will earn $2.37 per share for the quarter, down from their prior forecast of $2.40. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q4 2025 earnings at $2.36 EPS, Q3 2026 earnings at $2.51 EPS and Q4 2026 earnings at $2.48 EPS.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts’ consensus estimates of $2.06 by $0.28. The firm had revenue of $984.17 million during the quarter, compared to analysts’ expectations of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.27 EPS.

Several other equities analysts have also recently commented on CRL. Robert W. Baird increased their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the company a “neutral” rating in a research note on Thursday, May 8th. Evercore ISI upgraded Charles River Laboratories International from an “in-line” rating to an “outperform” rating and set a $170.00 target price for the company in a research note on Thursday, May 8th. Cowen upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Wednesday, May 14th. TD Cowen upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $179.00 target price for the company in a research note on Wednesday, May 14th. Finally, The Goldman Sachs Group cut Charles River Laboratories International from a “buy” rating to a “neutral” rating and reduced their target price for the company from $190.00 to $170.00 in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $171.85.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $135.51 on Friday. The stock has a market cap of $6.66 billion, a P/E ratio of 903.40, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The stock has a 50 day moving average of $129.03 and a 200-day moving average of $160.75. Charles River Laboratories International has a 52 week low of $91.86 and a 52 week high of $254.15.

Hedge Funds Weigh In On Charles River Laboratories International

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Charles River Laboratories International by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company’s stock valued at $1,136,938,000 after acquiring an additional 60,497 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Charles River Laboratories International by 5.1% during the first quarter. Wellington Management Group LLP now owns 4,285,012 shares of the medical research company’s stock valued at $644,980,000 after acquiring an additional 208,586 shares during the period. Kayne Anderson Rudnick Investment Management LLC boosted its holdings in shares of Charles River Laboratories International by 8.0% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,950,273 shares of the medical research company’s stock valued at $293,555,000 after acquiring an additional 144,732 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of Charles River Laboratories International by 2.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock valued at $330,231,000 after acquiring an additional 47,221 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Charles River Laboratories International by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company’s stock valued at $227,042,000 after acquiring an additional 14,787 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Buying and Selling

In other news, EVP Joseph W. Laplume sold 500 shares of the business’s stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the transaction, the executive vice president now owns 19,513 shares of the company’s stock, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).